Abstract-Compartmentation of intracellular signaling pathways serves as an important mechanism conferring the specificity of G protein-coupled receptor (GPCR) signaling. In the heart, stimulation of ␤ 2 -adrenoceptor (␤ 2 -AR), a prototypical GPCR, activates a tightly localized protein kinase A (PKA) signaling, which regulates substrates at cell surface membranes, bypassing cytosolic target proteins (eg, phospholamban). Although a concurrent activation of ␤ 2 -AR-coupled G i proteins has been implicated in the functional compartmentation of PKA signaling, the exact mechanism underlying the restriction of the ␤ 2 -AR-PKA pathway remains unclear. In the present study, we demonstrate that phosphatidylinositol 3-kinase (PI3K) plays an essential role in confining the ␤ 2 -AR-PKA signaling. Inhibition of PI3K with LY294002 or wortmannin enables ␤ 2 -AR-PKA signaling to reach intracellular substrates, as manifested by a robust increase in phosphorylation of phospholamban, and markedly enhances the receptor-mediated positive contractile and relaxant responses in cardiac myocytes. These potentiating effects of PI3K inhibitors are not accompanied by an increase in ␤ 2 -AR-induced cAMP formation. Blocking G i or G␤␥ signaling with pertussis toxin or ␤ARK-ct, a peptide inhibitor of G␤␥, completely prevents the potentiating effects induced by PI3K inhibition, indicating that the pathway responsible for the functional compartmentation of ␤ 2 -AR-PKA signaling sequentially involves G i , G␤␥, and PI3K. Thus, PI3K constitutes a key downstream event of ␤ 2 -AR-G i signaling, which confines and negates the concurrent 
A fundamental question of G protein-coupled receptor (GPCR) signal transduction is how a myriad of GPCRs and numerous cognate G proteins can elicit highly specific physiological responses. One of the most notable determinants of the specificity and effector-selectivity of receptor signaling is the cellular compartment over which the signal can transmit. As a prototypical GPCR, ␤-adrenoceptor (AR) activates the classical G s -adenylyl cyclase (AC)-cAMPprotein kinase A (PKA) signaling cascade. In the heart, PKA subsequently phosphorylates a multitude of regulatory proteins involved in cardiac muscle contraction, including sarcolemmal L-type Ca 2ϩ channel, 1 the sarcoplasmic reticulum (SR) Ca 2ϩ pump regulator phospholamban (PLB), 2 and myofilament proteins, 3 resulting in increased contractility and accelerated cardiac relaxation.
However, a large body of evidence indicates that ␤ 2 -ARinduced cAMP/PKA signaling is tightly localized to the cell surface membrane microdomains in the vicinity of L-type Ca 2ϩ channels and cannot transmit to non-sarcolemmal target proteins, whereas ␤ 1 -AR-mediated cAMP/PKA signaling can broadcast throughout the cell. 4 Specifically, ␤ 1 -AR can activate sarcolemmal L-type Ca 2ϩ channels and increase phosphorylation of multiple intracellular proteins, such as PLB at SR membrane and troponin I and C proteins of myofilaments, resulting in both positive contractile and relaxant responses. [5] [6] [7] [8] [9] [10] [11] [12] In contrast, ␤ 2 -AR stimulation selectively activates the Ca 2ϩ channel, without affecting the aforementioned intracellular PKA target proteins, leading to a positive inotropic effect in the absence of a relaxant effect. 4, 7, 13 Moreover, studies with patch-clamp single-channel recordings have shown that in both cardiac myocytes 14 and hippocampal neurons, 15 ␤ 2 -AR stimulation modulates single L-type Ca 2ϩ channel activity only in a local mode (agonist included within the patch pipette with tip diameter Ϸ1.0 m) and not in a remote mode (agonist perfused outside the patch), whereas ␤ 1 -AR stimulation increases the channel activity in both modes.
The spatial and functional restriction of ␤ 2 -AR/G s -induced cAMP/PKA signaling might be explained by the additional coupling of the receptor to G i proteins. 8, 12, 16 Inhibition of G i signaling with pertussis toxin (PTX) allows ␤ 2 -AR stimulation to induce PLB phosphorylation 5 and to modulate single L-type Ca 2ϩ channels in the remote mode. 14 Although the G i pathway is implicated in the functional compartmentation of ␤ 2 -AR-mediated cAMP/PKA signaling, the downstream events of the ␤ 2 -AR-G i pathway remain largely unknown.
Phosphoinositide 3-kinases (PI3Ks) are group of enzymes exhibiting both lipid kinase and protein kinase activities, and are broadly engaged in multiple vital cellular functions, including cell proliferation, cytoskeletal organization, cell migration, cell survival and cell growth. [17] [18] [19] [20] [21] Based on their structure and substrate specificity, PI3Ks can be divided into 3 classes (I, II, and III), and the class I PI3Ks can be further categorized into 2 subclasses (A and B). The class I B PI3K (also known as PI3K␥) can be activated by G␤␥ subunits of G proteins. 22 Our recent studies have shown that PI3K constitutes a downstream mediator of ␤ 2 -AR-G i signaling to deliver a cell survival signal, which protects heart muscle cells against a wide range of apoptotic insults such as hypoxia, reactive oxygen species, and enhanced ␤ 1 -AR stimulation. 23, 24 However, to date, there is no information available regarding the possible involvement of PI3K in acute modulation of cardiac function. Moreover, it remains unexplored whether PI3K participates in the G i -dependent functional compartmentation of ␤ 2 -AR-PKA signaling, thereby reshaping the PKA-mediated protein phosphorylation and cardiac functional modulation.
The goal of the present investigation is to determine the possible involvement of PI3K in the functional restriction and effector-selectivity of the ␤ 2 -AR/G s -mediated PKA signaling. We show that inhibition of PI3K by PI3K inhibitors enables ␤ 2 -AR-PKA signaling to reach intracellular proteins, as evidenced by a robust increase in PKA-dependent phosphorylation of PLB, a major regulator of cardiac relaxation, and that overexpression of constitutively active PI3K reduces basal phosphorylation of PLB. In the presence of the PI3K inhibitor, ␤ 2 -AR-induced PLB phosphorylation is associated with a de novo relaxant effect and an increase in the receptor-mediated positive contractile response. These potentiating effects induced by PI3K inhibition are fully prevented by disrupting G i or G␤␥ signaling, suggesting that the pathway linking G i activation to the functional compartmentation of ␤ 2 -AR-activated PKA signaling sequentially involves G i , G␤␥, and PI3K.
Materials and Methods

Measurements of Cell Length and Intracellular Ca 2؉ Transients
Single ventricular myocytes were isolated from 2-to 4-month-old rat hearts by a standard enzymatic technique. 25 Animals were provided by Charles River Laboratories (Wilmington, Mass), and the protocol of the study was approved by the Animal Care and Use Committee of the Gerontology Research Center, National Institute on Aging. In some experiments, heart cells were treated with 1.5 g/mL PTX (Sigma) for 3 hours at 37°C to block G i signaling, as described previously. 8 In another subset experiments, myocytes were loaded with a fluorescent Ca 2ϩ probe, indo-1/acetoxymethyl-ester (Molecular Probes), and then electrically paced at 0.5 Hz at 23°C, as described previously. 25 
PI3K Activity Assay
Suspensions of adult rat cardiomyocytes were first incubated with appropriate pharmacological agents. Measurement of PI3K activity was then performed, as previously described. 23 Measurements of cAMP Accumulation and PKA-Dependent Phosphorylation of Phospholamban at Ser 16 Intracellular cAMP was measured, as previously described. 28 PKAdependent phosphorylation of phospholamban (PLB) at Ser 16 was assayed as described previously. 5, 10 Protein concentration was determined by the method of Lowry et al, 26 using ovalbumin as standard. After electrophoresis, the Western blot was performed as described previously. 5, 10 Culture and Adenoviral Infection of Adult Rat Ventricular Myocytes
In some experiments, heart cells were cultured and infected with adenovirus-p110* (constitutively active PI3K), 27 adenovirus-␤ARK-ct (an adenovirus vector encoding ␤ARK1 carboxyl-terminal domain, which blocks G␤␥ signaling, kindly provided by R.J. Lefkowitz and W.J. Koch at Duke University, Durham, NC) or adenovirus-␤-gal (an adenovirus vector expressing lacZ, as a negative control), all at multiplicity of infection (moi) of 100, as previously described. 24 All experiments were performed after 24 hours of adenoviral infection.
Statistics
All quantitative data are expressed as meanϮSE. The results were analyzed using ANOVA. Differences were considered significant when values were PϽ0.05.
Results
␤ 2 -AR Stimulation Increases PI3K Activity
To determine the role of PI3K in the functional compartmentation of ␤ 2 -AR signaling, we first examined the possible effect of ␤ 2 -AR stimulation on PI3K activity using a lipid kinase assay to monitor the conversion of PI into PI-P. 23 As shown in Figure 1 , ␤ 2 -AR stimulation by zinterol for 15 minutes increases PI-P production by Ϸ2.5-fold, and the addition of a highly selective ␤ 1 -AR antagonist, CGP20712A (0.3 mol/L), does not alter this effect (data not shown). Stimulation of insulin-like growth factor-1 for 15 minutes, a known PI3K activator, 29 is used as a positive control. LY294002 (5 mol/L for 15 minutes), a PI3K inhibitor, 30 completely blocks agonist-induced increase in PI3K activity. This result is consistent with our previous findings that ␤ 2 -AR stimulation activates PI3K in mouse and neonatal rat cardiac myocytes. 23, 24 
Inhibition of PI3K Enhances ␤ 2 -AR-Mediated Contractile Response
Next, we evaluated the potential involvement of PI3K in ␤ 2 -AR-mediated cardiac functional modulation with respect to single cell contraction and intracellular Ca 2ϩ (Ca i ) handling. The PI3K inhibitor, LY294002, whereas it effectively blocks agonist-induced PI3K activation (Figure 1 ), has no significant effect on the amplitude and kinetics of baseline myocyte contraction (Table) . However, LY294002 markedly enhances ␤ 2 -AR-mediated increase in cell contractility. Figure 2B illustrates the average dose-response of zinterol. The PI3K inhibitor shifts the whole dose-response curve upward and leftward, thus reducing the EC 50 of zinterol from 3ϫ10 Ϫ7 to 5ϫ10 Ϫ8 mol/L. To further determine the possible effect of PI3K inhibition on ␤ 2 -AR-induced change in Ca i transient, indexed by indo-1 fluorescent ratio, 25 we simultaneously measured the Ca i transient and contraction in freshly isolated adult rat cardiomyocytes loaded with indo-1 ( Figure 2C ). In the absence of LY294002, ␤ 2 -AR stimulation by zinterol (0.1 mol/L, a concentration of ϷEC 50 ) increases the amplitudes of contraction and Ca i transient to 162.3Ϯ13.2% and 124.4Ϯ4.0% of control, respectively ( Figures 2C and 2D ). Although LY294002 alone has no significant effect on either parameter (Table 1) , it enhances zinterol-induced increases in the contraction and Ca i transient by Ϸ2-fold and Ϸ1.5-fold, respectively ( Figures 2C and 2D , also see Figures 7A and 2B). This result indicates that PI3K, known as a key molecule mediating the ␤ 2 -AR antiapoptotic effect, 23, 24 can acutely regulate cardiac contraction and Ca i handling during ␤ 2 -AR stimulation.
Inhibition of PI3K Enables ␤ 2 -AR Stimulation to Induce a De Novo Relaxant Effect
In addition to augmenting ␤ 2 -AR-induced positive inotropic effect, inhibition of PI3K by LY294002 overtly augments the effects of ␤ 2 -AR on the kinetics of contraction and Ca i transient. As shown in Figure 2E , zinterol alone only slightly reduces the half relaxation time (t 1/2 ) of contraction and has virtually no effect on the t 1/2 of Ca i transient, consistent with previous reports. [5] [6] [7] [8] 13 However, in the presence of LY294002, ␤ 2 -AR stimulation causes a robust relaxant effect, as manifested by the significantly abbreviated t 1/2 of both parameters (84.7Ϯ1.3% and 84.5Ϯ4.1% of control for contraction and Ca i transient, respectively) (Figures 2C and 2E ; also see Figures 7C and 7D) . Because cardiac relaxant effect is a hallmark of PKA-dependent phosphorylation of PLB, the present data suggests that inhibition of PI3K permits ␤ 2 -AR stimulation to evoke a de novo relaxant effect, likely by affecting phosphorylation status of PLB, the major regulator of cardiac SR Ca 2ϩ pump. 2 To test this hypothesis, we next measured ␤ 2 -AR-induced PLB phosphorylation in the presence or absence of PI3K inhibition.
PI3K Inhibition Enables ␤ 2 -AR Stimulation to Increase Phosphorylation of PLB at Ser 16
Previous studies have shown that PLB is phosphorylated by ␤ 1 -AR stimulation at 2 adjacent sites, Ser 16 and Thr 17 , catalyzed by PKA and Ca 2ϩ /calmodulin-dependent kinase II, respectively, 2,31 whereas ␤ 2 -AR stimulation is unable to induce phosphorylation of PLB and other cytosolic regulatory proteins. 5, 7, 9, 10 Consistent with the previous notion, the ␤ 2 -AR agonist, zinterol, has only a very minor effect on PKA- Figures 3A and 3B , respectively. Zinterol even at a maximal concentration (10 mol/L) only increases Ser 16 -PLB phosphorylation by 1.2-fold. In sharp contrast, in LY294002-pretreated myocytes, ␤ 2 -AR stimulation by zinterol results in a dose-dependent increase in PLB phosphorylation, with a maximal effect of 3.8-fold increase and an EC 50 of 3.2ϫ10 Ϫ7 mol/L. The inhibitory effect of PI3K on ␤ 2 -AR-induced PLB phosphorylation is further confirmed by using another PI3K inhibitor, wortmannin. 32 Similar to LY294002, wortmannin also allows the ␤ 2 -AR agonist, zinterol, to increase PKAdependent phosphorylation of PLB at Ser 16 in a dosedependent manner ( Figures 3A and 3B) . These results indicate that inhibition of PI3K enables ␤ 2 -AR to induce PLB phosphorylation at Ser 16 , thus resulting in a de novo relaxant effect. This provides the first evidence that PI3K is critically involved in the functional compartmentation and effectorselectivity of ␤ 2 -AR signaling.
Overexpression of Constitutively Active PI3K Decreases Phosphorylation of PLB at Ser 16 To further examine the possible role of PI3K on PKAdependent PLB phosphorylation, we expressed a constitutively active PI3K (Adv-p110*) in cultured adult rat cardiomyocytes using adenoviral gene transfer. In myocytes overexpressing the constitutively active PI3K, basal phosphorylation of PLB at Ser 16 is reduced by Ϸ50% as compared with that in myocytes-infected by a control virus (Adv-␤-gal, at the same moi) ( Figures 4A and 4B) , suggesting that activation of PI3K per se inhibits PKAdependent phosphorylation of PLB. Interestingly, in myocytes expressing the constitutively active PI3K, pretreatment of cells with LY294002 (5 mol/L for 10 minutes) cannot unmask ␤ 2 -AR-induced PLB phosphorylation, whereas it fully abolishes agonist-induced endogenous PI3K activation (Figure 1 ). This is consistent with the fact that LY294002 (5 mol/L) is unable to inhibit the constitutively active PI3K-induced phosphorylation of Akt, a downstream effect of PI3K (data not shown, also see Wu et al 27 ). This result indicates that the potentiating effect of LY294002 on ␤ 2 -AR-induced PLB phosphorylation at Ser 16 is mediated specifically by inhibiting of PI3K activity.
Inhibition of PI3K by LY294002 Cannot Enhance ␤ 2 -AR-Induced cAMP Formation
To understand the mechanism underlying the potentiating effects of PI3K inhibition on ␤ 2 -AR-induced PLB phosphorylation, we next measured intracellular cAMP formation in response to ␤ 2 -AR stimulation in the presence and absence of the PI3K inhibitor, LY294002 ( Figure 5 ). ␤ 2 -AR stimulation by zinterol (0.1 mol/L, a concentration of ϷEC 50 ) significantly increases cAMP accumulation by Ϸ2-fold. However, pretreatment of cells with LY294002 cannot further enhance zinterol-induced increase in intracellular cAMP accumulation. This result suggests that the confining effect of ␤ 2 -AR-PI3K on the concurrent ␤ 2 -AR-G s signaling is likely mediated by activating protein phosphatases, rather than by inhibiting formation of cAMP.
Disruption of G i Signaling and Inhibition of PI3K Have Nonadditive Effect on ␤ 2 -AR-Induced
Phosphorylation of PLB at Ser 16 We hypothesized that if PI3K activation is the downstream event of G i signaling, disruption of G i signaling by PTX treatment and inhibition of PI3K should have nonadditive effect on ␤ 2 -AR-induced phosphorylation of PLB at Ser 16 . Indeed, pretreatment of cells with both PTX and LY294002 exhibits no additive effect on PLB phosphorylation in response to the ␤ 2 -AR agonist, zinterol (0.1 mol/L, a dose the ϷEC 50 used to avoid saturation). Cotreatment of cells with PTX and LY294002 enhances the response of PLB phosphorylation by Ϸ2.2-fold, similar to the single treatment of cells by either PTX or LY294002 (Figures 6A and 6B) . The same conclusion is drawn when even a lower dose of zinterol (10 nmol/L) is utilized (1.8Ϯ0.4-, 1.9Ϯ0.4-, and 1.8Ϯ0.5-fold increase for PTXϩzinterol, LY294002ϩzinterol, and PTXϩLY294002ϩzinterol, respectively, nϭ6, PϾ0.05 among groups), indicating that the nonadditive effect is not due to a saturation of PLB phosphorylation. Taken together, these results strongly suggest that the additional G i coupling offsets ␤ 2 -AR-stimulated PLB phosphorylation via a PI3K-dependent mechanism.
Disruption of G i Signaling Prevents the Potentiating Effects Induced by PI3K Inhibition
In PTX-treated cells, the PI3K inhibitor fails to further enhance the ␤ 2 -AR-induced augmentation in contraction amplitude ( Figure 7A) , consistent with the data on PLB phosphorylation described above. This is not caused by a saturation of cell contractile response, because the contraction amplitude can be increased by about 4-fold in response to a full ␤-AR agonist, isoproterenol (1 mol/L) (data not shown). Likewise, LY294002 does not significantly alter the response of Ca i transient in those PTX-treated cells ( Figure  7B ). Furthermore, PTX treatment prevents LY294002 to potentiate the ␤ 2 -AR-mediated abbreviation in the t 1/2 of contraction or Ca i transient ( Figures 7C and 7D) . Thus, inhibition of G i signaling completely abolishes the potentiating effects of the PI3K inhibitor on ␤ 2 -AR-mediated positive contractile and relaxant responses. This indicates that ␤ 2 -AR stimulation activates PI3K signaling via a G i -dependent mechanism.
␤ 2 -AR-Mediated PI3K Activation Requires G␤␥ Signaling
We next sought to discriminate which subunit of heterotrimeric G i proteins is essential to the PI3K activation by infecting myocytes with either adenovirus-␤ARK-ct (␤ARK-ct, a peptide inhibitor of G␤␥ signaling) 33 or adenovirus-␤-gal (as a negative control). It is noteworthy that the basal contraction or Ca i transient in cells infected with adenovirus-␤ARK-ct is comparable to that in myocytes infected by the control virus, adenovirus-␤-gal (Table) . Figure 7E shows that in adenovirus-␤-gal-infected myocytes inhibition of PI3K by LY294002 augments zinterol-induced increase in the contraction amplitude, similar to the situation in freshly isolated myocytes (Figures 2 and 7A) . However, in myocytes infected by adenovirus-␤ARK-ct, LY294002 fails to further enhance ␤ 2 -AR-evoked positive inotropic effect. Similarly, inhibition of G␤␥ signaling prevents LY294002 from potentiating the ␤ 2 -AR-mediated increase in the Ca i transient ( Figure 7F ). These observations suggest that G␤␥ subunits dissociated from G i proteins are critically involved in ␤ 2 -AR-mediated activation of PI3K in cardiac myocytes.
Discussion
PI3K Functionally Restricts ␤ 2 -AR-Mediated cAMP/PKA Signaling
Our present study shows that inhibition of PI3K also enables ␤ 2 -AR to induce PLB phosphorylation as well as a de novo relaxant response in adult rat cardiomyocytes, and that overexpression of a constitutively active PI3K significantly decreases the basal phosphorylation of PLB. The potentiating effects caused by PI3K inhibition are completely prevented by blocking either G i or G␤␥ signaling, indicating that the G i -dependent restriction of ␤ 2 -AR-PKA signaling involves a G i -G␤␥-PI3K pathway. Thus, in addition to its essential roles in the regulation of chronic cellular processes such as proliferation, cell migration, cell survival, and cell growth, PI3K constitutes an important molecular link responsible for the functional compartmentation of ␤ 2 -AR/G s -PKA signaling, negating the ␤ 2 -AR/G s -mediated phosphorylation of PKA target proteins and the positive cardiac contractile and relaxant responses.
Possible Mechanisms Underlying the Inhibitory Effect of PI3K on ␤ 2 -AR-PKA Signaling
The present result demonstrates that the PI3K inhibitor LY294002 markedly enhances the response of contraction or Ca i transient to ␤ 2 -AR stimulation (Figure 2 ). This enhancement can be largely explained by the increase in PLB phosphorylation at Ser 16 ( Figure 3) . It is widely accepted that increased PKA-dependent phosphorylation of PLB not only accelerates SR Ca 2ϩ uptake, but also elevates SR Ca 2ϩ content due to the increased Ca 2ϩ pump activity, 2 thereby leading to hastened cardiac relaxation and increased cardiac contractil- ity. This is supported by the notion that in a PLB-deficient mouse model (a functional equivalent of PLB full phosphorylation), both cardiac contractility and relaxation velocity are significantly enhanced as compared with that in wild-type animals. 34 Alternatively, inhibition of PI3K might enhance ␤ 2 -AR-induced increase in L-type Ca 2ϩ currents, which could elevate the amplitudes of Ca 2ϩ transient and contraction. However, it has been recently shown that activation of PI3K increases the L-type Ca 2ϩ current in vascular smooth muscle cells. 35 Nevertheless, the possible effect of PI3K on cardiac Ca 2ϩ currents awaits future investigation. It has been demonstrated that PI3K exerts both lipid kinase and protein kinase activities. 17, 18 Interestingly, the present results show that inhibition of PI3K markedly enhances ␤ 2 -AR-induced phosphorylation of PLB at Ser 16 by PKA (Figure 3 ), suggesting that PI3K may cause dephosphorylation of phosphorylated PLB-Ser 16 . Because inhibition of PI3K by LY294002 does not affect zinterol-induced increase in cAMP formation ( Figure 5 ) and inhibition of G i signaling does not attenuate ␤ 2 -AR/G s -induced increase in total cellular cAMP production 13 or in PKA activity, 5 the inhibitory effect of PI3K on ␤ 2 -AR-evoked PLB phosphorylation might occur downstream of cAMP/PKA, perhaps via direct or indirect activation of certain protein phosphatases. In this regard, emerging evidence suggests that ␤ 2 -AR is able to form a macromolecular signaling complex with protein phosphatase 2A. 15 Moreover, calyculin A, an inhibitor of protein phosphatase 1 and 2A, potentiates ␤ 2 -AR-induced positive inotropic effect in a PTX-sensitive manner, 5 suggesting that protein phosphatases might be engaged in ␤ 2 -AR/G i signaling. In this scenario, PI3K might act as a protein kinase to increase protein phosphatase activity directly via phosphorylation or indirectly through phosphorylation and subsequent inactivation of endogenous protein phosphatase inhibitor-I. Further study is merited to address these issues.
Regarding the involvements of specific PI3K isoenzymes in ␤ 2 -AR/G i signaling, previous studies have shown that the class IB PI3K (PI3K␥ isoform) is a downstream target of G␤␥ signaling. 22 However, recent studies suggest that in cultured neonatal rat cardiac myocytes, stimulation of ␤-AR (subtype not specified) may activate PI3K␣ and ␤. 36 Because of the lack of isoform-specific PI3K inhibitors, the present study cannot discriminate the specific isoenzymes of PI3K family involved in ␤ 2 -AR-coupled G i signaling in adult rat cardiac myocytes.
Potential Involvement of PI3K in Agonist-Induced ␤ 2 -AR Desensitization and Its Pathophysiological Relevance
As is true for all of GPCRs, the exposure of a receptor to an agonist results in rapid diminishment in its signaling efficiency (referred to as desensitization). Agonist-dependent ␤ 2 -AR desensitization is initiated by phosphorylation of the activated receptor by members of the GPCR kinase family, particularly the ␤-adrenergic receptor kinase-1 (␤ARK1). 37 It is noteworthy that PI3K is able to physically associate with ␤ARK1 and promote agonist-dependent ␤-AR internalization, 38 perhaps contributing to agonist-dependent ␤-AR desensitization. The robust inhibitory effect of PI3K activation on ␤ 2 -AR-induced positive contractile and relaxant responses, demonstrated by the present results, raises an intriguing and important question regarding the possible requirement of PI3K for agonist-induced ␤ 2 -AR desensitization.
Although activation of ␤ 2 -AR/G i -mediated PI3K pathway protects cardiac myocytes against apoptosis, 23, 24 an imbalance of ␤ 2 -AR-initiated G s and G i signaling cascades may have pathological consequences. Both recent in vivo and in vitro studies have demonstrated that activation of PI3K signaling is coincident with heart muscle cell hypertrophy in response to pressure overload or ␤-AR stimulation. 36, 39 In addition, in many kinds of chronic heart failure in human and animal models, the contractile response to ␤-AR stimulation is markedly diminished, 40, 41 which is accompanied by enhanced G i signaling. 42 It is speculated that the upregulation of ␤ 2 -AR-G i signaling in the functionally compensated hypertrophic heart or in the early stages of heart failure may protect against myocyte apoptosis and consequently slow the progression of cardiomyopathy and contractile dysfunction. However, the exaggerated ␤ 2 AR-G i signaling may blunt the G s -mediated contractile support, contributing to the phenotype of decompensated heart failure.
